18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA
LeonaBio, Inc. 2026 Annual Meeting Results; 84.19% Shares Voted
Annual Report to Security Holders
Reports First Quarter 2026 Financial Results and Provides Business Update
Investor Presentation
LeonaBio, Inc. Approves 2026 Equity Incentive Plan at Special Meeting
Announces Name Change to LeonaBio, Inc. with New Ticker 'LONA'
Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million, Investor Presentation
Amended material disclosure
Q1
FY 2025
Q3
Q2
FY 2023
Q2 amended
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload